{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.4","value":"-6.0"},{"groupId":"OG001","spread":"25.6","value":"-7.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"39"}],"units":"Participants"}],"description":"scale ranged from 0 to 100 with higher score meaning greater quality of life","dispersionType":"Standard Deviation","groups":[{"description":"etopodide, doxorubicin, cisplatin and mitotane\n\nEtoposide\n\nDoxorubicin\n\nCisplatin\n\nMitotane\n\nparticipants who progressed during first line therapy, were eligible to the alternative treatment (Sz-M)","id":"OG000","title":"EDP-M"},{"description":"streptozotocin and mitotane\n\nStreptozotocin\n\nMitotane\n\nparticipants who progressed during first line therapy, were eligible to the alternative treatment (EDP-M)","id":"OG001","title":"Sz-M"}],"paramType":"MEAN","populationDescription":"participants with data on both time points","reportingStatus":"POSTED","timeFrame":"baseline and 8 weeks","title":"Change in Quality of Life as Measured by QLQ-C30","type":"SECONDARY","unitOfMeasure":"units on a scale"}